Cell Source, Inc. (CLCS) financial statements (2022 and earlier)

Company profile

Business Address 57 WEST 57TH STREET
NEW YORK, NY 10019
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 2452819371719
Cash and cash equivalents 2452819371719
Prepaid expense 17857391257275
Deferred costs     125 
Other current assets 303083613526
Total current assets: 45211566532338121
Noncurrent Assets
Property, plant and equipment   (3)(3)12
Deferred costs     28 
Other undisclosed noncurrent assets    3  
Total noncurrent assets:   (3) 302
Other undisclosed assets   3   
TOTAL ASSETS: 45211566532368123
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 2,1821,327953202586234
Accounts payable 193135278   
Accrued liabilities 1,1601,052533821115 
Employee-related liabilities 101012 12969
Taxes payable 122118116147  
Interest and dividends payable 697121410925 
Other undisclosed accounts payable and accrued liabilities    (875)435(735)
Debt 1,2381,1121,4631,174708 
Deferred compensation liability 724661588627325 
Derivative instruments and hedges, liabilities  3522016283,2802,319
Due to related parties 150150222150181100
Other liabilities  236100100450 
Other undisclosed current liabilities 4,1051,875 2,2095201,254
Total current liabilities: 8,4005,7123,5265,0896,0503,907
Noncurrent Liabilities
Long-term debt and lease obligation     72 
Long-term debt, excluding current maturities     72 
Liabilities, other than long-term debt     4 
Accounts payable and accrued liabilities     4 
Other undisclosed noncurrent liabilities  145    
Total noncurrent liabilities:  145  76 
Other undisclosed liabilities   1,460   
Total liabilities: 8,4005,8574,9865,0896,1263,907
Stockholders' equity
Stockholders' equity attributable to parent, including: (7,947)(5,742)(4,920)(4,557)(5,758)(3,784)
Preferred stock 1  1  
Common stock 332726252424
Additional paid in capital 17,72515,37611,7239,9704,7204,191
Accumulated deficit (25,706)(21,146)(16,670)(14,553)(10,503)(7,998)
Warrants and rights outstanding      420
Other undisclosed stockholders' equity attributable to parent  11  (420)
Total stockholders' equity: (7,947)(5,742)(4,920)(4,557)(5,758)(3,784)
TOTAL LIABILITIES AND EQUITY: 45211566532368123

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2015
12/31/2014
Operating expenses (3,638)(3,903)(2,006)(2,293)(2,320)(4,055)
Operating loss: (3,638)(3,903)(2,006)(2,293)(2,320)(4,055)
Nonoperating expense (922)(573)(111)(790)(184)(3)
Investment income, nonoperating 17 (210)   
Interest and debt expense 134194(191)(725)(36) 
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes (134)(194)(260)48536 
Loss from continuing operations before income taxes: (4,560)(4,475)(2,569)(3,323)(2,504)(4,057)
Income tax expense (benefit) 2,4242,524717(22)6461,151
Loss before gain (loss) on sale of properties: (2,136)(1,951)(1,852)(3,345)(1,858)(2,906)
Other undisclosed net loss  (2,524)    
Net loss: (2,136)(4,475)(1,852)(3,345)(1,858)(2,906)
Other undisclosed net income (loss) attributable to parent (2,424) (266)263(646)(1,151)
Net loss attributable to parent: (4,560)(4,475)(2,117)(3,083)(2,504)(4,057)
Other undisclosed net loss available to common stockholders, basic (878)(742)    
Net loss available to common stockholders, diluted: (5,438)(5,217)(2,117)(3,083)(2,504)(4,057)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2015
12/31/2014
Net loss: (2,136)(4,475)(1,852)(3,345)(1,858)(2,906)
Comprehensive loss, net of tax, attributable to parent: (2,136)(4,475)(1,852)(3,345)(1,858)(2,906)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: